MiNK Therapeutics and Memorial Sloan Kettering to Present Phase II Study on agenT-797 with Checkpoint Inhibitors for PD-1 Refractory Gastroesophageal Cancer at AACR 2026

MiNK Therapeutics and Memorial Sloan Kettering Cancer Center will present findings from a Phase II study evaluating the combination of agenT-797 with checkpoint inhibitors in patients with PD-1 refractory gastroesophageal cancer. The presentation is scheduled to take place at the American Association for Cancer Research (AACR) Annual Meeting 2026. The study focuses on patients whose cancers have not responded to prior PD-1 inhibitor treatments, exploring the potential benefits of this novel therapeutic approach.

The research investigates agenT-797, an invariant natural killer T (iNKT) cell therapy, in combination with checkpoint inhibitors to assess its efficacy and safety profile in treating advanced gastroesophageal cancer. This collaboration between MiNK Therapeutics and Memorial Sloan Kettering highlights ongoing efforts to address treatment-resistant forms of cancer. The AACR meeting will provide a platform for sharing detailed data and insights from this clinical trial, contributing to broader discussions within the oncology community about emerging therapies for challenging cancer cases.

Newsflash | Powered by GeneOnline AI

Source: GO-AI-ne1

For any suggestion and feedback, please contact us.

Date: April 3, 2026

Author

GOAI